The association between antidepressant use and deaths from road traffic accidents: a case-crossover study
- 122 Downloads
Antidepressants are some of the most commonly used psychiatric medications, but little information is available about the effects of antidepressant treatment on the risk of traffic accidents across classes of antidepressants or associated with each substance individually. To investigate the relationship between exposure to antidepressants and risk of fatality in road traffic accidents.
We used a Korean national road traffic authority database linked with a national health insurance database between January 1, 2010 and December 31, 2014 and applied a case-crossover design. The study subjects were drivers in South Korea who died from traffic accidents and who had prescriptions for antidepressants within 1 year prior to the date of the accident. We compared the status of prescription for antidepressants with the hazard period and four matched control periods using conditional logistic regression, adjusting for other drug use. The trends of antidepressant utilization were described in terms of the number of prescriptions. A case–case-time-control design was applied to drugs with an increasing trend in use and a significant case-crossover odds ratio (OR).
A total of 1250 antidepressant-using drivers were included, and an increased risk was observed during the 30-day hazard period (adjusted OR 1.30; 95% CI 1.03–1.63). Selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) showed significant risks, but tricyclic antidepressants did not. However, the associations of all antidepressants, SSRIs, SNRIs, escitalopram, and duloxetine did not remain significant after adjusting for trends in utilization. Paroxetine and milnacipran were associated with increased risks, with no obvious increase in their utilization, but the possibility of confounding by indication could have affected the results for milnacipran.
Considering the trends of antidepressant prescription and utilization, the use of paroxetine increased the risk of fatal traffic accidents.
KeywordsAntidepressants Traffic accidents Case-crossover design Pharmacoepidemiology
The research was promoted as part of the ‘Technology Development for Behavior Improvement and Violation Control of High Risk Drivers’ program that was carried out by the Ministry of Land, Infrastructure and Transport in Korea (Grant Number 14TLRP-B085437-01). The funding body did not play a role in the study design, writing of the manuscript, or in the decision to submit the manuscript for publication.
Compliance with ethical standards
Conflict of interest
The authors declared no conflict of interest.
- 5.Won E, Park SC, Han KM, Sung SH, Lee HY, Paik JW, Jeon HJ, Lee MS, Shim SH, Ko YH, Lee KJ, Han C, Ham BJ, Choi J, Hwang TY, Oh KS, Hahn SW, Park YC, Lee MS, Clinical Research Center for D (2014) Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition. J Korean Med Sci 29(4):468–484. https://doi.org/10.3346/jkms.2014.29.4.468 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Sansone RA, Sansone LA (2009) Driving on antidepressants: cruising for a crash? Psychiatry (Edgmont) 6(9):13–16Google Scholar
- 8.Dassanayake T, Michie P, Carter G, Jones A (2011) Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 34(2):125–156. https://doi.org/10.2165/11539050-000000000-00000 CrossRefPubMedGoogle Scholar
- 11.Rapoport MJ, Herrmann N, Molnar F, Rochon PA, Juurlink DN, Zagorski B, Seitz D, Morris JC, Redelmeier DA (2008) Psychotropic medications and motor vehicle collisions in patients with dementia. J Am Geriatr Soc 56(10):1968–1970. https://doi.org/10.1111/j.1532-5415.2008.01903.x CrossRefPubMedGoogle Scholar
- 18.Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, Do CH, Song JS, Hyon Bang J, Ha S, Lee EJ, Ae Shin S (2017) Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol 46(3):799–800. https://doi.org/10.1093/ije/dyw253 CrossRefPubMedGoogle Scholar
- 21.Maclure M, Mittleman MA (2000) Should we use a case-crossover design? Annu Rev Publ Health 21:193–221. https://doi.org/10.1146/annurev.publhealth.21.1.193 CrossRefGoogle Scholar
- 22.Hooper TI, DeBakey SF, Pearse L, Pratt S, Hoffman KJ (2010) The use of electronic pharmacy data to investigate prescribed medications and fatal motor vehicle crashes in a military population, 2002–2006. Accid Anal Prev 42(1):261–268. https://doi.org/10.1016/j.aap.2009.07.024 CrossRefPubMedGoogle Scholar
- 23.Bjorkenstam C, Moller J, Ringback G, Salmi P, Hallqvist J, Ljung R (2013) An association between initiation of selective serotonin reuptake inhibitors and suicide—a nationwide register-based case-crossover study. Plos One 8(9):e73973. https://doi.org/10.1371/journal.pone.0073973 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Fournier JP, Wilchesky M, Patenaude V, Suissa S (2015) Concurrent use of benzodiazepines and antidepressants and the risk of motor vehicle accident in older drivers: a nested case-control study. Neurol Ther 4(1):39–51. https://doi.org/10.1007/s40120-015-0026-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Wijlaars LP, Nazareth I, Whitaker HJ, Evans SJ, Petersen I (2013) Suicide-related events in young people following prescription of SSRIs and other antidepressants: a self-controlled case series analysis. BMJ Open 3(9):e003247. https://doi.org/10.1136/bmjopen-2013-003247 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Campagne DM (2005) Venlafaxine and serious withdrawal symptoms: warning to drivers. Medscape Gen Med 7(3):22Google Scholar
- 34.Schmitt JA, Ramaekers JG, Kruizinga MJ, van Boxtel MP, Vuurman EF, Riedel WJ (2002) Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 16(3):207–214. https://doi.org/10.1177/026988110201600303 CrossRefPubMedGoogle Scholar
- 36.Iwamoto K, Takahashi M, Nakamura Y, Kawamura Y, Ishihara R, Uchiyama Y, Ebe K, Noda A, Noda Y, Yoshida K, Iidaka T, Ozaki N (2008) The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. Hum Psychopharmacol 23(5):399–407. https://doi.org/10.1002/hup.939 CrossRefPubMedGoogle Scholar
- 40.Poirier MF, Galinowski A, Amado I, Longevialle R, Bourdel MC, Tournoux A, Serre C, Loo H (2004) Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol 19(1):1–7. https://doi.org/10.1002/hup.557 CrossRefPubMedGoogle Scholar
- 41.Korea Institute of Drug Safety and Risk Management (2015) Instruction of changing the label according to the results of re-examination study. https://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do?bbsId=BBSMSTR_000000000051&nttId=1521. Accessed 14 Dec 2018
- 42.Korean Society for Affective Disorders and Korean College of Neuropsychopharmacology, Korean Medication Algorithm Project for Depressive Disorder (2012) http://www.theksad.or.kr/data/etc/beflmp19FIOW.pdf. Accessed 14 Dec 2018
- 44.Charlton J, Koppel S, Odell M, Devlin A, Langford J, O’Hare M, Kopinathan C, Andrea D, Smith G, Khodr B (2010) Influence of chronic illness on crash involvement of motor vehicle drivers. Monash University Accident Research Center (MUARC), ClaytonGoogle Scholar